American Association for Cancer Research
Browse

Supplementary Figure S2 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Download (610.6 kB)
journal contribution
posted on 2024-09-16, 11:33 authored by Qingsheng Xu, Kaiyuan Huang, Xiangqi Meng, Yuxiang Weng, Luyuan Zhang, Linghao Bu, Xiujue Zheng, Jinquan Cai, Renya Zhan, Qun Chen

Axial, sagittal and coronal gadolinium-enhanced and FLAIR MRI at pre-baseline (A-D). Three months later, MRI demonstrated progressive disease after anlotinib plus temozolomide (E-H).

History

ARTICLE ABSTRACT

Background: Glioblastoma (GBM) is a highly vascularized tumor with few treatment options after disease recurrence. Here, we report the efficacy and safety of anlotinib hydrochloride plus temozolomide in patients with recurrent GBM. Methods: Patients with first definite postsurgical progression of histologically confirmed GBM preceded by standard radiotherapy and temozolomide chemotherapy were eligible for inclusion. All patients received temozolomide (150-200mg/m2, orally, QD, d1-5/4wks) and anlotinib (10mg, orally, QD, d1-14/3wks) until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed 6-month PFS rate by RANO criteria. Result: Twenty-one patients were enrolled between May 2020 and July 2021, with a median age of 55 (range 27-68) years old. According to the RANO criteria, tumor response occurred in 17 patients, of which 9 patients had a complete response, and the objective response rate was 81.0% (95% CI 62.6-99.3). The disease control rate was 95.2% (95% CI 76.2-99.9), with three additional patients achieving a stable disease without tumor progression. The median PFS was 7.3 months (95% CI 4.9-9.7), and the 6-month PFS rate was 61.9% (95% CI 39.3-84.6). The median overall OS was 16.9 months (95% CI 7.8-26.0). The most common adverse events were leukocytopenia (66.7%), thrombocytopenia (38.1%), and hypertriglyceridemia (38.1%). Five patients had nine grade 3 adverse events, with a 23.8% incidence rate. Two patients discontinued therapy due to ischemic stroke (grade 3) and wound dehiscence (grade 1) respectively. No grade 4 or treatment-related deaths occurred in this study. Conclusions: Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC